Thermo Fisher Scientific, the global leader in serving science, and Arsenal Biosciences, Inc. , a cell therapy clinical development company, to develop novel chimeric...
Xeris Biopharma Holdings , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...
Thermo Fisher Scientific Inc, the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for...
AbbVie announced topline results from a Phase 2 study of upadacitinib given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib,...
